Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT05160168 is registered in ClinicalTrials.gov with Theseus Pharmaceuticals as lead sponsor.

NCT NCT05160168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Lead sponsor
Theseus Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
January 3, 2022
Completion date
February 2, 2024
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system disease, digestive system neoplasm, gastrointestinal diseases, gastrointestinal neoplasms, gastrointestinal stromal tumors (gist), neoplasms, neoplasms by histologic type, neoplasms, connective and soft tissue, neoplasms, connective tissue